Zengin Mehmet, Zergeroğlu Sema, Okcu Oğuzhan, Benek Suat
Department of Pathology, Kırıkkale University, Kırıkkale, Turkey.
Recep Tayyip Erdoğan University, Training and Research Hospital, Rize, Turkey.
Cell Oncol (Dordr). 2021 Apr;44(2):423-432. doi: 10.1007/s13402-020-00579-5. Epub 2021 Jan 19.
Immune responses have long been an area of interest in cancer research. In this study, the effects of programmed cell death-1 (PD-1) and its ligand (PD-L2) on the prognosis of colorectal cancer (CRC) were investigated.
Primary tumour specimens of stage III CRC patients operated between 2002 and 2013 were assessed for PD-1 and PD-L2 expression and various clinicopathological and prognostic factors.
We observed a significant relationship between poor prognostic factors and PD-1/PD-L2 expression. These biomarkers were also found to serve as independent risk factors for LIR and MSI. In univariate analysis, relapse-free survival (RFS) and overall survival (OS) rates were found to be poor in PD-1 and PD-L2 positive patients. In multivariate analysis, these biomarkers were found to serve as independent poor prognostic factors for RFS and OS.
Our data indicate that PD-1 and PD-L2 may serve as independent prognostic survival parameters for CRC patients and may be employed for the design of targeted therapies.
免疫反应长期以来一直是癌症研究的一个热点领域。在本研究中，研究了程序性细胞死亡蛋白1（PD-1）及其配体（PD-L2）对结直肠癌（CRC）预后的影响。
对2002年至2013年间接受手术的III期CRC患者的原发性肿瘤标本进行PD-1和PD-L2表达以及各种临床病理和预后因素的评估。
我们观察到不良预后因素与PD-1/PD-L2表达之间存在显著关系。这些生物标志物还被发现是LIR和MSI的独立危险因素。在单变量分析中，发现PD-1和PD-L2阳性患者的无复发生存率（RFS）和总生存率（OS）较差。在多变量分析中，这些生物标志物被发现是RFS和OS的独立不良预后因素。
我们的数据表明，PD-1和PD-L2可能作为CRC患者独立的预后生存参数，并可用于靶向治疗的设计。
